Bioxytran, Inc. filed an 8-K on March 13, 2026, disclosing amendments to its Certificate of Designation of Convertible Preferred Stock and Certificate of Designation, approved by the Board, along with a performance-based equity award to an officer. These actions modify rights of security holders and involve compensatory arrangements for certain officers.
Key takeaways
Company approved and filed amendment to Certificate of Designation of Convertible Preferred Stock.
Board approved performance-based equity award to Da.
Filed Certificate of Amendment to Certificate of Designation.
Exhibit 3.1: Certificate of Amendment filed with Nevada Secretary of State on February 18, 2026.
Impacts material modification to rights of security holders.